Help Your Migraine Patients Access Effective, Drug-Free Therapy.
Advocate for Insurance Coverage Today.
Affordable access to the Nerivio® REN wearable for your migraine patients
The FDA-cleared Nerivio REN wearable is an effective and life-changing migraine treatment for adults and children as young as 8 years old. However, for too many people, access to the Nerivio REN wearable does not exist since some insurance companies are not covering the cost of the treatment.
No one should have to face the choice between paying high out-of-pocket costs or going without essential migraine care.
Insurance denials are on the rise—77% of healthcare providers report more denials than ever—but continued advocacy elevates your voice.1 By taking action, you’re not only helping your patients, you’re helping secure accessible, affordable migraine care for all.
Patient care should come first. Health insurance shouldn’t be a barrier.
Safe and effective treatment for migraine disease is important, especially in pediatric years it can reduce the risk of chronification, helping patients avoid long-term disability and embrace healthier, more active futures.2
If you have patients who could benefit from the Nerivio REN wearable, reach out to our Market Access team.
Based on Strong Scientific Evidence
Studies demonstrate that Nerivio provides safe and consistent migraine relief in the clinical and real-world setting. Data from our 22 peer reviewed publications include:
Achieved pain relief with Nerivio
Demonstrated sustained pain relief and pain freedom at 24 hours
Achieved higher relief with Nerivio than with medications*
Reduction of 4 migraine days per month
Experienced ≥50% reduction in moderate to severe headache days
No device-related adverse events reported in the clinical study
Achieved pain relief with Nerivio
Achieved pain freedom with Nerivio
Did not use prescription medications
Migraine patients are navigating access and affordability. Hear how limited insurance coverage affects their lives.
Alexandra & Elizabeth Fuller Share Their Challenges with Insurance Coverage
Dr. Torphy Offers Insights Into How Limited Insurance Coverage Affects Young Patients
Holly & Claire DeLuca Share Their Challenges with Insurance Coverage
Fill out the form to check coverage or connect with the Nerivio team
References
- Experian Health, “State of Claims 2024: Insights from survey findings”, 2024.
- Charles et al, "Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification", 2009.
- Werner et al, "Acute treatment of migraine in children aged 6–11: Real‐world analysis of Remote Electrical Neuromodulation (REN), Annals of the Child Neurology Society, 2024.
- Hershey et al, "Remote electrical neuromodulation for acute treatment of migraine in adolescents: A randomized, double-blind, sham-controlled study", Headache, 2020.
- Hershey et al, "Remote electrical neuromodulation for acute treatment of migraine in adolescents: Post hoc analysis of a randomized controlled trial", Pain Medicine, 2021.
- Tepper et al, "Remote electrical neuromodulation for acute treatment of migraine: A real-world analysis", Headache, 2023.
- Yarnitsky et al, "Nonpainful remote electrical neuromodulation for acute treatment of migraine: A multicenter, double-blind, randomized study", Neurology, 2019.
- Aliai et al, "Remote electrical neuromodulation for migraine treatment: A systematic review and meta-analysis", The Journal of Headache and Pain, 2022.
* In a post-hoc analysis, 71.4% of patients achieved pain relief vs 57.1% of patients with medications (p<0.001).